Faridi JS - Search Results

1

Pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinolines: Novel compounds that reverse ABCG2-mediated resistance in cancer cells.

Karthikeyan C, Malla R, Ashby CR Jr, Amawi H, Abbott KL, Moore J, Chen J, Balch C, Lee C, Flannery PC, Trivedi P, Faridi JS, Pondugula SR, Tiwari AK. Karthikeyan C, et al. Among authors: faridi js. Cancer Lett. 2016 Jun 28;376(1):118-26. doi: 10.1016/j.canlet.2016.03.030. Epub 2016 Mar 21. Cancer Lett. 2016. PMID: 27012188

2

Anti-tumor pyrimidinylpiperazines bind to the prosurvival Bcl-2 protein family member Bcl-XL.

Shallal HM, Faridi JS, Russu WA. Shallal HM, et al. Among authors: faridi js. Bioorg Med Chem Lett. 2011 Mar 1;21(5):1325-8. doi: 10.1016/j.bmcl.2011.01.054. Epub 2011 Jan 28. Bioorg Med Chem Lett. 2011. PMID: 21300543

3

Genetic ablation of PRAS40 improves glucose homeostasis via linking the AKT and mTOR pathways.

Malla R, Wang Y, Chan WK, Tiwari AK, Faridi JS. Malla R, et al. Among authors: faridi js. Biochem Pharmacol. 2015 Jul 1;96(1):65-75. doi: 10.1016/j.bcp.2015.04.016. Epub 2015 Apr 27. Biochem Pharmacol. 2015. PMID: 25931147

4

Proline-rich AKT substrate of 40-kDa (PRAS40) in the pathophysiology of cancer.

Malla R, Ashby CR Jr, Narayanan NK, Narayanan B, Faridi JS, Tiwari AK. Malla R, et al. Among authors: faridi js. Biochem Biophys Res Commun. 2015 Jul 31;463(3):161-6. doi: 10.1016/j.bbrc.2015.05.041. Epub 2015 May 20. Biochem Biophys Res Commun. 2015. PMID: 26003731 Review.

5

Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer.

Shah KN, Wilson EA, Malla R, Elford HL, Faridi JS. Shah KN, et al. Among authors: faridi js. Mol Cancer Ther. 2015 Nov;14(11):2411-21. doi: 10.1158/1535-7163.MCT-14-0689. Epub 2015 Sep 2. Mol Cancer Ther. 2015. PMID: 26333382

6

A truncated human Ah receptor suppresses growth of human cervical tumor xenografts by interfering with hypoxia signaling.

Wang D, Faridi JS, Li Y, Chan WK. Wang D, et al. Among authors: faridi js. FEBS Lett. 2009 Sep 17;583(18):3039-44. doi: 10.1016/j.febslet.2009.08.013. Epub 2009 Aug 18. FEBS Lett. 2009. PMID: 19695250 Free PMC article.

7

AKT-induced tamoxifen resistance is overturned by RRM2 inhibition.

Shah KN, Mehta KR, Peterson D, Evangelista M, Livesey JC, Faridi JS. Shah KN, et al. Among authors: faridi js. Mol Cancer Res. 2014 Mar;12(3):394-407. doi: 10.1158/1541-7786.MCR-13-0219. Epub 2013 Dec 20. Mol Cancer Res. 2014. PMID: 24362250

8

Molecular Targeting of RRM2, NF-κB, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer.

Wilson EA, Sultana N, Shah KN, Elford HL, Faridi JS. Wilson EA, et al. Among authors: faridi js. Mol Cancer Ther. 2021 Apr;20(4):655-664. doi: 10.1158/1535-7163.MCT-20-0373. Epub 2021 Feb 3. Mol Cancer Ther. 2021. PMID: 33536192

9

Estrogen, tamoxifen, and Akt modulate expression of putative housekeeping genes in breast cancer cells.

Shah KN, Faridi JS. Shah KN, et al. Among authors: faridi js. J Steroid Biochem Mol Biol. 2011 Jul;125(3-5):219-25. doi: 10.1016/j.jsbmb.2011.03.005. Epub 2011 Mar 21. J Steroid Biochem Mol Biol. 2011. PMID: 21420492

10

Expression of constitutively active Akt-3 in MCF-7 breast cancer cells reverses the estrogen and tamoxifen responsivity of these cells in vivo.

Faridi J, Wang L, Endemann G, Roth RA. Faridi J, et al. Clin Cancer Res. 2003 Aug 1;9(8):2933-9. Clin Cancer Res. 2003. PMID: 12912939

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

16 results

Search Page

Filters